Evusheld (Bebtelovimab)
Experts are hopeful that this preventive medication, taken before any exposure to COVID-19, will provide an extra layer of protection to those who may not mount a full immune response to the vaccine - Kelsey Kloss
image by: The Elliot Lewis Center
Resources
FDA pulls Evusheld authorization as coronavirus evolution quashes another therapy
The Food and Drug Administration on Thursday withdrew the authorization of Evusheld, the latest antibody therapy to be rendered ineffective by the mutations the virus has picked up. Notably, Evusheld — unlike other antibody therapies — was not for infected patients, but rather was given as a pre-exposure treatment to people at high risk for severe Covid-19, such as those with compromised immune systems.
The End of Evusheld
If you’re immunocompromised, this … isn’t great.
Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
Only antibody therapy authorised in US for pre-exposure prophylaxis. Pivotal phase III data showed robust efficacy and long-term protection with one dose in high-risk population.
Hospitals use a lottery to allocate scarce COVID drugs for the immunocompromised
The government provides Evusheld to states based on their total adult populations. The approach doesn't prioritize where the need is greatest.
What to Know About Evusheld, the New Monoclonal Antibody Drug to Prevent COVID-19 in the Immunocompromised
Experts are hopeful that this preventive medication, taken before any exposure to COVID-19, will provide an extra layer of protection to those who may not mount a full immune response to the vaccine.
‘I felt this huge relief’: how antibody injections could free the immunosuppressed under Covid
FDA expected to issue full emergency authorization for periodic antibody injections, or PrEP, to complement vaccinations.
Evusheld
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product EVUSHELDTM (tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg)...
Introducing Stitches!
Your Path to Meaningful Connections in the World of Health and Medicine
Connect, Collaborate, and Engage!
Coming Soon - Stitches, the innovative chat app from the creators of HWN. Join meaningful conversations on health and medical topics. Share text, images, and videos seamlessly. Connect directly within HWN's topic pages and articles.